TY - JOUR T1 - Therapeutic Efficacy and Inhibitory Mechanism of Regorafenib Combined With Radiation in Colorectal Cancer JF - In Vivo JO - In Vivo SP - 3217 LP - 3224 DO - 10.21873/invivo.12157 VL - 34 IS - 6 AU - YU-CHANG LIU AU - I-TSANG CHIANG AU - JING-GUNG CHUNG AU - JUNG-HUNG HSIEH AU - CHIH-HUNG CHIANG AU - MAO-CHI WENG AU - FEI-TING HSU AU - YUAN-HAO LEE AU - CHENG-SHYONG CHANG AU - SONG-SHEI LIN Y1 - 2020/11/01 UR - http://iv.iiarjournals.org/content/34/6/3217.abstract N2 - Background: Although both chemotherapy and radiotherapy (RT) can sufficiently maintain tumor suppression of colorectal cancer (CRC), these treatments may trigger the expression of nuclear factor kappa B (NF-κB) and compromise patients' survival. Regorafenib suppresses NF-κB activity in various tumor types. However, whether regorafenib may act as a suitable radiosensitizer to enhance therapeutic efficacy of RT remains unknown. Materials and Methods: Here, we established a CRC-bearing animal model to investigate the therapeutic efficacy of regorafenib in combination with RT, through measurement of tumor growth, body weight, whole-body computed tomography (CT) scan and immunohisto-chemistry staining. Results: Smallest tumor size and weight were found in the combination treatment group. In addition, RT-induced up-regulation of NF-κB and downstream proteins were diminished by regorafenib. Moreover, the body weight and liver pathology in the treated group were similar to those of the non-treated control group. Conclusion: Regorafenib may enhance the anti-CRC efficacy of RT. ER -